ELTXNew hire, new options
Elicio Therapeutics said it granted 21,210 inducement stock options to a new employee on April 15. The options were priced at $11.78 a share, which was the stock’s closing price that day.
Why this matters
This isn’t a blockbuster pipeline update or an FDA plot twist. It’s more like the company saying, “Hey, come work here and we’ll sweeten the deal with equity.” That’s common in biotech, where cash is precious and stock awards help lure talent.
The fine print, because of course there is fine print
The grant vests over four years:
- 25% on the first anniversary of the employee’s start date
- the rest monthly after that
- all subject to continued service
So yes, this is a pretty standard retention setup. But for investors, the main takeaway is the same old biotech tradeoff: attracting people who can move the science forward, while slowly adding more shares to the mix.
Big picture: not the kind of headline that changes the whole story, but it does tell you Elicio is still actively hiring and using equity as the carrot.